Psychedelic Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Psilocybin, Ketamine), By Application (Treatment-Resistant Depression, Opiate Addiction), By Distribution Channel (Online, Offline), And By Geography - Forecasts From 2024 To 2029

  • Published : Jan 2024
  • Report Code : KSI061616499
  • Pages : 149

The psychedelic drugs market is anticipated to grow at a steady pace during the projected period.

Psychedelic drugs, also referred to as hallucinogens, are compounds that affect emotion, perception, and different parts of the brain. These drugs have the power to significantly alter consciousness, reality perception, and cognitive processes. LSD (lysergic acid diethylamide), psilocybin (found in certain mushrooms, also called "magic mushrooms" or "shrooms"), DMT (dimethyltryptamine), MDMA (3,4-methylenedioxymethamphetamine, sometimes called "ecstasy"), and mescaline (found in peyote cactus) are a few well-known psychedelics.

Growth drivers for psychedelic drugs

Several scientific studies have revealed possible therapeutic advantages for mental health issues, prompting a re-examination of psychedelic drugs in clinical settings fuelling the market. Media attention and well-known supporters have contributed to a shift in public opinion that has elevated psychedelics from illegal drugs to perhaps useful therapeutic aids. The increased interest has been attributed to a larger societal movement towards holistic well-being and the acceptance of alternative therapies. Furthermore, the psychedelic industry's economic potential has drawn investment, bolstering the field's research and growth.

Increasing prevalence of mental health problems

The increasing number of people experiencing mental health issues is anticipated to increase the need for novel therapies. This could spark interest in more studies into the medical uses of psychedelic substances. For instance, in the US, mental diseases are widespread. More than one in five persons in the United States are thought to suffer from a mental disease (57.8 million in 2021). A wide range of diseases, from mild to moderate to severe, are included in the category of mental illnesses.

Therapeutic Potential

The market for psychedelic drugs is changing on several fronts due to the drugs’ medicinal potential. Research and development efforts into them are increasing because of mounting evidence of their effectiveness in treating a range of mental health issues, from PTSD to depression. Significant funding is drawn in by this growing scientific interest, which promotes the creation of drugs and cures using psychedelic drugs. Public acceptability is growing beyond recreational use as attitudes change, impacting legal changes in some areas and fostering a more hospitable atmosphere for market expansion.

Growth in research and studies

The market for psychedelic drugs is changing in part due to the increase in research and studies on these substances. Thorough scientific research on these drugs' therapeutic potential strengthens their legitimacy and supports their usage in the treatment of disorders including PTSD, anxiety, and depression. The development of psychedelic-assisted therapies and clinical studies is accelerated by the inflow of funding from venture capitalists and pharmaceutical firms, which supports the expansion of the industry overall. The market for psychedelic substances is growing and presents chances for corporations as research reveals new therapeutic applications and target demographics.

Increasing investment and industry growth

The psychedelic drugs market is changing due to increased investment and business expansion. Financial support is driving research and development initiatives, enabling a more thorough and rigorous investigation of the potential medicinal applications of psychedelics. This increased scientific study spurs innovation, broadens the range of possible uses, and advances knowledge of their processes of action. The possibility of regulatory approvals for certain therapeutic purposes increases with larger and more robust clinical studies made possible by increasing expenditure, which is a crucial step towards popular adoption. The market as a whole is expanding due to the rising industrial expansion, which encourages competition, and product diversity.

The Ketamine drug segment is anticipated to hold a significant market share

Ketamine is predicted to be a significant participant in the psychedelic drug market due to its special qualities and therapeutic applications. In clinical and scientific contexts, ketamine has drawn interest because of its potential to treat depression and mood disorders. Ketamine's remarkable ability to produce therapeutic effects quickly sets it apart from other psychiatric medications. Interest in ketamine's potential therapeutic applications has grown as a result of its clinical use, particularly in the off-label use and infusion therapy for depression that is resistant to conventional treatments. Additionally, ketamine's clearance by the FDA to treat depression that is resistant to therapy as well as continued research and development efforts point to a broader understanding of the drug's significance.

The psychedelic drugs market in the North American region is anticipated to grow steadily. 

The psychedelic drugs market in North America is driven by several important factors that support the industry's expansion. The region's growing emphasis on research and clinical trials where universities, research groups, and pharmaceutical companies are actively investigating the therapeutic potential of psychedelic substances, particularly in addressing mental health disorders is a major driver. Another important aspect is the shifting legal climate. Several North American states are moving towards decriminalization or decreased penalties for specific psychedelics, which is creating a more lenient atmosphere for research and therapeutic uses.

Market Key Developments

  • In June 2023, to draw attention to important factors for researchers looking into the use of psychedelic substances for the treatment of medical illnesses, such as psychiatric or substance use disorders, the U.S. Food and Drug Administration released a new draft guidance. This is the first draft guideline from the FDA that gives industry advice on how to plan clinical studies for psychedelic medications.
  • In February 2023, The U.S. Food and Drug Administration (FDA) accepted the submission of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD), according to Biogen Inc. and Sage Therapeutics, Inc.


  • By Drug Type
    • Psilocybin
    • Ketamine
  • By Application
    • Treatment-Resistant Depression
    • Opiate Addiction
  • By Distribution Channel
    • Online
    • Offline
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Psilocybin

5.3. Ketamine


6.1. Introduction

6.2. Treatment-Resistant Depression

6.3. Opiate Addiction


7.1. Introduction

7.2. Online

7.3. Offline


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. MindMed

10.2. Cybin

10.3. Eleusis Ltd

10.4. Atal Life Sciences

10.5. Compass Pathways

10.6. Psygen

10.7. Filament Health

10.8. Silo Pharma

10.9. Freedom Biosciences



Eleusis Ltd

Atal Life Sciences

Compass Pathways


Filament Health

Silo Pharma

Freedom Biosciences